CA2595889C - N-halogenated amino acids and n,n-dihalogenated amino acids in combination with hypohalous acids - Google Patents
N-halogenated amino acids and n,n-dihalogenated amino acids in combination with hypohalous acids Download PDFInfo
- Publication number
- CA2595889C CA2595889C CA2595889A CA2595889A CA2595889C CA 2595889 C CA2595889 C CA 2595889C CA 2595889 A CA2595889 A CA 2595889A CA 2595889 A CA2595889 A CA 2595889A CA 2595889 C CA2595889 C CA 2595889C
- Authority
- CA
- Canada
- Prior art keywords
- group
- acid
- hydrogen
- lower alkyl
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002253 acid Substances 0.000 title claims description 117
- 150000001413 amino acids Chemical class 0.000 title description 56
- 150000007513 acids Chemical class 0.000 title description 26
- 239000000203 mixture Substances 0.000 claims abstract description 211
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 71
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 65
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 46
- 239000000645 desinfectant Substances 0.000 claims abstract description 40
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 29
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 28
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 28
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 27
- 230000003330 sporicidal effect Effects 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims description 94
- 229910052739 hydrogen Inorganic materials 0.000 claims description 92
- 239000001257 hydrogen Substances 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- 229910052799 carbon Inorganic materials 0.000 claims description 41
- 150000001721 carbon Chemical group 0.000 claims description 40
- 208000015181 infectious disease Diseases 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 39
- 150000002148 esters Chemical class 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 33
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 241000894006 Bacteria Species 0.000 claims description 25
- 125000001246 bromo group Chemical group Br* 0.000 claims description 25
- 125000001589 carboacyl group Chemical group 0.000 claims description 21
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 235000013305 food Nutrition 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 9
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 229910006069 SO3H Inorganic materials 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- QYNRGGHZWCUZLK-UHFFFAOYSA-N 2-(dichloroamino)-2-methylpropane-1-sulfonic acid Chemical compound ClN(Cl)C(C)(C)CS(O)(=O)=O QYNRGGHZWCUZLK-UHFFFAOYSA-N 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- KBINJLBTMJFAPH-UHFFFAOYSA-N 2-(chloroamino)-2-methylpropane-1-sulfonic acid Chemical compound ClNC(C)(C)CS(O)(=O)=O KBINJLBTMJFAPH-UHFFFAOYSA-N 0.000 claims description 4
- JJQITYDTBUXIDS-UHFFFAOYSA-N 2-(dibromoamino)-2-methylpropane-1-sulfonic acid Chemical compound BrN(Br)C(C)(C)CS(O)(=O)=O JJQITYDTBUXIDS-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- VHVPQPYKVGDNFY-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-AVQIMAJZSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000002140 halogenating effect Effects 0.000 claims description 2
- 229910004727 OSO3H Inorganic materials 0.000 claims 2
- DLPSCCOICQJPPT-UHFFFAOYSA-N 1-(chloroamino)propane-2-sulfonic acid Chemical compound OS(=O)(=O)C(C)CNCl DLPSCCOICQJPPT-UHFFFAOYSA-N 0.000 claims 1
- YIBKSASUZFBMOU-UHFFFAOYSA-N 1-(dichloroamino)propane-2-sulfonic acid Chemical compound OS(=O)(=O)C(C)CN(Cl)Cl YIBKSASUZFBMOU-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 15
- 239000000243 solution Substances 0.000 description 169
- 229940024606 amino acid Drugs 0.000 description 95
- CNZIVXGNLPHOKV-UHFFFAOYSA-N 2-(dichloroamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCN(Cl)Cl CNZIVXGNLPHOKV-UHFFFAOYSA-N 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 71
- -1 13-alanine Chemical compound 0.000 description 54
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 42
- 238000011282 treatment Methods 0.000 description 42
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 39
- 206010052428 Wound Diseases 0.000 description 35
- 208000027418 Wounds and injury Diseases 0.000 description 34
- NMMHHSLZJLPMEG-UHFFFAOYSA-N 2-(chloroamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNCl NMMHHSLZJLPMEG-UHFFFAOYSA-N 0.000 description 25
- 238000004659 sterilization and disinfection Methods 0.000 description 24
- 229960003080 taurine Drugs 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 230000002378 acidificating effect Effects 0.000 description 18
- 244000052769 pathogen Species 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 125000002346 iodo group Chemical group I* 0.000 description 17
- 206010017533 Fungal infection Diseases 0.000 description 16
- 208000031888 Mycoses Diseases 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 208000028169 periodontal disease Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- 108091006629 SLC13A2 Proteins 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 230000002070 germicidal effect Effects 0.000 description 8
- 208000007565 gingivitis Diseases 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 231100001274 therapeutic index Toxicity 0.000 description 8
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 208000036142 Viral infection Diseases 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000003929 acidic solution Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 238000011203 antimicrobial therapy Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 150000005690 diesters Chemical class 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- XCJGLBWDZKLQCY-UHFFFAOYSA-N 2-methylpropane-2-sulfonic acid Chemical compound CC(C)(C)S(O)(=O)=O XCJGLBWDZKLQCY-UHFFFAOYSA-N 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000005708 Sodium hypochlorite Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000005202 decontamination Methods 0.000 description 5
- 230000003588 decontaminative effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000013580 millipore water Substances 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 150000003009 phosphonic acids Chemical class 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- VAUDXPRANUFYEC-UHFFFAOYSA-N 2-(chloroamino)-5-phosphonopentanoic acid Chemical compound OC(=O)C(NCl)CCCP(O)(O)=O VAUDXPRANUFYEC-UHFFFAOYSA-N 0.000 description 4
- COIDHHVBAVTJFV-UHFFFAOYSA-N 2-(dichloroamino)-5-phosphonopentanoic acid Chemical compound OC(=O)C(N(Cl)Cl)CCCP(O)(O)=O COIDHHVBAVTJFV-UHFFFAOYSA-N 0.000 description 4
- DRNNATGSBCVJBN-UHFFFAOYSA-N 2-amino-2-methylpropane-1-sulfonic acid Chemical compound CC(C)(N)CS(O)(=O)=O DRNNATGSBCVJBN-UHFFFAOYSA-N 0.000 description 4
- VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 102000003896 Myeloperoxidases Human genes 0.000 description 4
- 108090000235 Myeloperoxidases Proteins 0.000 description 4
- 229920000153 Povidone-iodine Polymers 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000002925 dental caries Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000000644 isotonic solution Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000003239 periodontal effect Effects 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 229960001621 povidone-iodine Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- BFMNKIRMUKIBRI-UHFFFAOYSA-N 2-(chloroamino)ethanesulfinic acid Chemical compound OS(=O)CCNCl BFMNKIRMUKIBRI-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229910001919 chlorite Inorganic materials 0.000 description 3
- 229910052619 chlorite group Inorganic materials 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 230000000249 desinfective effect Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- CHVZPRDGLWBEMJ-UHFFFAOYSA-N n-chlorobenzenesulfonamide Chemical compound ClNS(=O)(=O)C1=CC=CC=C1 CHVZPRDGLWBEMJ-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 230000000766 tuberculocidal effect Effects 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- DGSLPJDIFKVSIB-UHFFFAOYSA-N (1-azaniumyl-2-methylpropyl)-hydroxyphosphinate Chemical compound CC(C)C(N)P(O)(O)=O DGSLPJDIFKVSIB-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- SCFWQPHRDQRQIW-UHFFFAOYSA-N 2-(chloroamino)-8-phosphonooctanoic acid Chemical compound OC(=O)C(NCl)CCCCCCP(O)(O)=O SCFWQPHRDQRQIW-UHFFFAOYSA-N 0.000 description 2
- IHEFYJCAHPMNNZ-UHFFFAOYSA-N 2-(dichloroamino)-8-phosphonooctanoic acid Chemical compound OC(=O)C(N(Cl)Cl)CCCCCCP(O)(O)=O IHEFYJCAHPMNNZ-UHFFFAOYSA-N 0.000 description 2
- WYRXPDKKQWTPKX-UHFFFAOYSA-N 2-(dichloroamino)propane-1-sulfonic acid Chemical compound ClN(Cl)C(C)CS(O)(=O)=O WYRXPDKKQWTPKX-UHFFFAOYSA-N 0.000 description 2
- LDSLVJUAHMPZBB-UHFFFAOYSA-N 2-(diiodoamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCN(I)I LDSLVJUAHMPZBB-UHFFFAOYSA-N 0.000 description 2
- XUGMGYUIGNYMJQ-UHFFFAOYSA-N 2-(iodoamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNI XUGMGYUIGNYMJQ-UHFFFAOYSA-N 0.000 description 2
- KGGCRFYWXLVUQQ-UHFFFAOYSA-N 2-amino-8-phosphonooctanoic acid Chemical compound OC(=O)C(N)CCCCCCP(O)(O)=O KGGCRFYWXLVUQQ-UHFFFAOYSA-N 0.000 description 2
- OJFAFAAQEAAQJU-UHFFFAOYSA-N 2-aminoethanesulfinic acid;2-aminoethanesulfonic acid Chemical compound NCCS(O)=O.NCCS(O)(=O)=O OJFAFAAQEAAQJU-UHFFFAOYSA-N 0.000 description 2
- NETIXPOFUYPXNI-UHFFFAOYSA-N 2-aminopropane-2-sulfonic acid Chemical compound CC(C)(N)S(O)(=O)=O NETIXPOFUYPXNI-UHFFFAOYSA-N 0.000 description 2
- MWFMGBPGAXYFAR-UHFFFAOYSA-N 2-hydroxy-2-methylpropanenitrile Chemical compound CC(C)(O)C#N MWFMGBPGAXYFAR-UHFFFAOYSA-N 0.000 description 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- CEWZMYBSKUHYMS-UHFFFAOYSA-N 4-(chloroamino)-4-phosphonobutanoic acid Chemical compound OC(=O)CCC(NCl)P(O)(O)=O CEWZMYBSKUHYMS-UHFFFAOYSA-N 0.000 description 2
- DWYLYZGWBIVRGV-UHFFFAOYSA-N 4-(dichloroamino)-4-phosphonobutanoic acid Chemical compound OC(=O)CCC(N(Cl)Cl)P(O)(O)=O DWYLYZGWBIVRGV-UHFFFAOYSA-N 0.000 description 2
- SODXFOVXZATGPJ-UHFFFAOYSA-N 4-amino-4-phosphonobutanoic acid Chemical compound OP(=O)(O)C(N)CCC(O)=O SODXFOVXZATGPJ-UHFFFAOYSA-N 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 206010001076 Acute sinusitis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000194102 Bacillus intermedius Species 0.000 description 2
- OPIXQPCOZBIRMY-UHFFFAOYSA-N CC(C)CC(N)(C(O)=O)P(O)(O)=O Chemical compound CC(C)CC(N)(C(O)=O)P(O)(O)=O OPIXQPCOZBIRMY-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000004145 Endometritis Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010061977 Genital infection female Diseases 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 208000006595 Necrotizing Ulcerative Gingivitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- TWBUQKVVOGRLJB-UHFFFAOYSA-N OP(O)=O.CC(C)CN(Cl)Cl Chemical compound OP(O)=O.CC(C)CN(Cl)Cl TWBUQKVVOGRLJB-UHFFFAOYSA-N 0.000 description 2
- XOXKVCAPAVIKMN-UHFFFAOYSA-N OP(O)=O.CC(C)CNCl Chemical compound OP(O)=O.CC(C)CNCl XOXKVCAPAVIKMN-UHFFFAOYSA-N 0.000 description 2
- QCOBRPXSQOXIKA-UHFFFAOYSA-N OP(O)=O.CC(C)N(Cl)Cl Chemical compound OP(O)=O.CC(C)N(Cl)Cl QCOBRPXSQOXIKA-UHFFFAOYSA-N 0.000 description 2
- PNJUXBNLBKSYEX-UHFFFAOYSA-N OP(O)=O.CC(C)NCl Chemical compound OP(O)=O.CC(C)NCl PNJUXBNLBKSYEX-UHFFFAOYSA-N 0.000 description 2
- VUYULLVXTYXCNM-UHFFFAOYSA-N OP(O)=O.CCCN(Cl)Cl Chemical compound OP(O)=O.CCCN(Cl)Cl VUYULLVXTYXCNM-UHFFFAOYSA-N 0.000 description 2
- TYXPBVASBMOTNC-UHFFFAOYSA-N OP(O)=O.CCCNCl Chemical compound OP(O)=O.CCCNCl TYXPBVASBMOTNC-UHFFFAOYSA-N 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- LORUMFRUUVBIJT-UHFFFAOYSA-N P(O)(O)=O.NCCC Chemical compound P(O)(O)=O.NCCC LORUMFRUUVBIJT-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 208000031650 Surgical Wound Infection Diseases 0.000 description 2
- 241001135235 Tannerella forsythia Species 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229940064804 betadine Drugs 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical class ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical class C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000005528 methosulfate group Chemical group 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000004999 sex organ Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 231100000440 toxicity profile Toxicity 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 206010051250 ureteritis Diseases 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- WTXXSZUATXIAJO-OWBHPGMISA-N (Z)-14-methylpentadec-2-enoic acid Chemical compound CC(CCCCCCCCCC\C=C/C(=O)O)C WTXXSZUATXIAJO-OWBHPGMISA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- MXTPRJXPLFGHEE-UHFFFAOYSA-N 1-amino-2-sulfosulfanylethane Chemical compound NCCSS(O)(=O)=O MXTPRJXPLFGHEE-UHFFFAOYSA-N 0.000 description 1
- XIGJZYVHLIRSFU-UHFFFAOYSA-N 2-(bromoamino)-5-phosphonopentanoic acid Chemical compound OC(=O)C(NBr)CCCP(O)(O)=O XIGJZYVHLIRSFU-UHFFFAOYSA-N 0.000 description 1
- WEOKHANPLNMHMF-UHFFFAOYSA-N 2-(chloroamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNCl.OS(=O)(=O)CCNCl WEOKHANPLNMHMF-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- DYGRPJWAYXRMQZ-UHFFFAOYSA-N 2-aminopropan-2-ylphosphonic acid Chemical compound CC(C)(N)P(O)(O)=O DYGRPJWAYXRMQZ-UHFFFAOYSA-N 0.000 description 1
- IIQRVJPJSCSKLI-UHFFFAOYSA-N 4-methoxy-2-nitrobenzenesulfonic acid;hydrate Chemical compound O.COC1=CC=C(S(O)(=O)=O)C([N+]([O-])=O)=C1 IIQRVJPJSCSKLI-UHFFFAOYSA-N 0.000 description 1
- NIRCAUPPZAUKDX-UHFFFAOYSA-N 5-benzyl-2-[[4-(3-chlorophenyl)piperazin-1-yl]methyl]-6-methylpyridazin-3-one Chemical compound O=C1C=C(CC=2C=CC=CC=2)C(C)=NN1CN(CC1)CCN1C1=CC=CC(Cl)=C1 NIRCAUPPZAUKDX-UHFFFAOYSA-N 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BAQUMIUAJDHQAI-UHFFFAOYSA-N CC(C)(C)OC(=O)OS(N)(=O)=O Chemical compound CC(C)(C)OC(=O)OS(N)(=O)=O BAQUMIUAJDHQAI-UHFFFAOYSA-N 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001363490 Monilia Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- NXTVQNIVUKXOIL-UHFFFAOYSA-N N-chlorotoluene-p-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCl)C=C1 NXTVQNIVUKXOIL-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- DARKVQOMVNRQNZ-JEDNCBNOSA-N OBO.CC(C)C[C@H](NCl)C(O)=O Chemical compound OBO.CC(C)C[C@H](NCl)C(O)=O DARKVQOMVNRQNZ-JEDNCBNOSA-N 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 208000007435 Periapical Abscess Diseases 0.000 description 1
- 208000009019 Pericoronitis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 101150030723 RIR2 gene Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000542420 Sphyrna tudes Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001473878 Streptococcus infantarius Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- BMGMQYRPZOGZFU-YFKPBYRVSA-N [(1r)-1-amino-3-methylbutyl]boronic acid Chemical compound CC(C)C[C@H](N)B(O)O BMGMQYRPZOGZFU-YFKPBYRVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- RLZXKARDPOFVNB-UHFFFAOYSA-N aziridine-1-carboxylic acid Chemical class OC(=O)N1CC1 RLZXKARDPOFVNB-UHFFFAOYSA-N 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical group CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000882 contact lens solution Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- KADXVMRYQRCLAH-UHFFFAOYSA-N n'-iodobutanediamide Chemical compound NC(=O)CCC(=O)NI KADXVMRYQRCLAH-UHFFFAOYSA-N 0.000 description 1
- SJUGPXBWZCQTKM-UHFFFAOYSA-N n-chloro-4-methylbenzenesulfonamide;sodium Chemical compound [Na].CC1=CC=C(S(=O)(=O)NCl)C=C1 SJUGPXBWZCQTKM-UHFFFAOYSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009701 normal cell proliferation Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- SATVIFGJTRRDQU-UHFFFAOYSA-N potassium hypochlorite Chemical compound [K+].Cl[O-] SATVIFGJTRRDQU-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 239000003128 rodenticide Substances 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- KDNCILYKSYKEFJ-UHFFFAOYSA-N sodium;benzenesulfonyl(chloro)azanide Chemical compound [Na+].Cl[N-]S(=O)(=O)C1=CC=CC=C1 KDNCILYKSYKEFJ-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 201000005128 suppurative periapical periodontitis Diseases 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64736605P | 2005-01-25 | 2005-01-25 | |
| US60/647,366 | 2005-01-25 | ||
| PCT/US2006/002875 WO2006081392A1 (en) | 2005-01-25 | 2006-01-25 | N-halogenated amino acids and n, n-dihalogenated amino acids in combination with hypohalous acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2595889A1 CA2595889A1 (en) | 2006-08-03 |
| CA2595889C true CA2595889C (en) | 2013-11-19 |
Family
ID=36441417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2595889A Expired - Fee Related CA2595889C (en) | 2005-01-25 | 2006-01-25 | N-halogenated amino acids and n,n-dihalogenated amino acids in combination with hypohalous acids |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7846971B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1896001B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5329095B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070098947A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101132785A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006208046B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0607302A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2595889C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2421157T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL184771A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007008928A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI386201B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006081392A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200706402B (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1656095T3 (en) * | 2003-08-18 | 2014-03-10 | Novabay Pharmaceuticals Inc | N, N-DIHALOGENG-GENERATED AMINO ACIDS AND DERIVATIVES |
| US8747882B2 (en) | 2005-04-21 | 2014-06-10 | Astra Tech Ab | Catheter assembly with bactericidal effect |
| US20090221989A1 (en) * | 2005-09-21 | 2009-09-03 | Novabay Pharmaceuticals Inc | System and method for the prevention and treatment of bacterial and fungal infections including urinary tract infections (uti) using a hypohalous acid composition |
| JP2009511493A (ja) * | 2005-10-06 | 2009-03-19 | ノバベイ・ファーマシューティカルズ・インコーポレイテッド | Ｎ−ハロゲン化アミノ酸を使用する、尿路感染症（ｕｔｉ）を含む細菌感染症および真菌感染症の予防のためのシステムおよび方法 |
| TW200843787A (en) * | 2006-12-29 | 2008-11-16 | Novabay Pharmaceuticals Inc | N-halogenated amino compounds and derivatives; compositions and methods of using them |
| EP2111252A4 (en) * | 2007-01-31 | 2010-12-01 | Adam Heller | MANAGEMENT OF PAIN BY ELECTROCHEMICAL PATHWAY |
| UY31057A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado que contiene acido alifatico |
| UY31058A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios |
| UY31056A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Fromulaciones aminocido n-halogenado y metodos de limpieza y desinfeccion |
| UY31059A1 (es) * | 2007-05-01 | 2008-10-31 | Alcon Res Ltd | Formulaciones de aminoacido n-halogenado |
| UY31055A1 (es) * | 2008-02-01 | 2008-10-31 | Alcon Res Ltd | Sales antimicrobianas de aminoacido n-halogenado |
| JP2011516578A (ja) * | 2008-04-10 | 2011-05-26 | ノバベイ・ファーマシューティカルズ・インコーポレイテッド | 気管支肺感染症の治療および予防のための組成物および方法 |
| CA2723262A1 (en) * | 2008-04-15 | 2009-10-22 | Waldemar Gottardi | Compositions and devices for antisepsis and anticoagulation |
| IL192262A (en) * | 2008-06-17 | 2016-05-31 | Z H T Eng Equipment And Tech Ltd | A polymer that releases drugs into the animal body, a medicinal product containing it and a method for its preparation |
| WO2010017405A1 (en) * | 2008-08-06 | 2010-02-11 | Adam Heller | Methods and compositions for the treatment of pain |
| US20100076089A1 (en) * | 2008-08-12 | 2010-03-25 | Novabay Pharmaceuticals, Inc. | Antimicrobial gel formulations |
| WO2010044862A1 (en) | 2008-10-17 | 2010-04-22 | Ai Medical Devices, Inc. | Endotracheal intubation device |
| CA2741667A1 (en) | 2008-11-07 | 2010-05-14 | Novabay Pharmaceuticals, Inc. | Antimicrobial n-chlorinated compositions |
| WO2010054009A1 (en) * | 2008-11-07 | 2010-05-14 | Novabay Pharmaceuticals, Inc. | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
| WO2010091280A1 (en) | 2009-02-06 | 2010-08-12 | Alcon Research, Ltd. | N-halogenated amino acid formulations comprising phosphine or amine oxides |
| RU2520034C2 (ru) * | 2009-03-18 | 2014-06-20 | ОЛАТЕК ИНДАСТРИЗ ЭлЭлСи | Соединения для лечения воспаления |
| US20100272783A1 (en) * | 2009-04-24 | 2010-10-28 | Novabay Pharmaceuticals, Inc. | Methods of Treating Infections of the Nail |
| US20110020474A1 (en) * | 2009-07-27 | 2011-01-27 | Novabay Pharmaceuticals, Inc. | Methods of Treating Infections of the Nail or Skin Using Hypohalite |
| EP2531026A4 (en) * | 2010-02-04 | 2013-09-25 | Novabay Pharmaceuticals Inc | ANTIMICROBIAL FORMULATIONS ON POLYSACCHARID BASE |
| US9888832B2 (en) | 2010-09-24 | 2018-02-13 | Blink Device LLC | Endotracheal intubation device |
| TWI407907B (zh) | 2010-10-04 | 2013-09-11 | Far Eastern New Century Corp | An antibacterial agent with water solubility and biodegradability |
| JP5952899B2 (ja) | 2011-06-15 | 2016-07-13 | アルエルエス グローバル アーベー | う蝕象牙質組織の検出と除去 |
| SE536581C2 (sv) | 2012-07-24 | 2014-03-11 | Rls Global Ab | Ett kit för behandling av sår eller liknande och ett preparat och metoder därav |
| US11814739B2 (en) | 2016-06-09 | 2023-11-14 | De Nora Holdings Us, Inc. | Electrolytic production of organic chloramine solutions |
| EP3745861A1 (en) * | 2018-01-30 | 2020-12-09 | Buckman Laboratories International, Inc. | Synergistic combinations of monochloramine and organic acid, and methods of using the same for microbial control |
| CN113729039A (zh) * | 2021-08-27 | 2021-12-03 | 上海罗克环控节能科技股份有限公司 | 一种绿色环保消毒液及其制造方法 |
| US12251486B2 (en) | 2021-09-09 | 2025-03-18 | Toyota Motor North America, Inc. | Vehicle sanitizing systems and methods for using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3998945A (en) * | 1972-06-12 | 1976-12-21 | National Patent Development Corporation | Dental treatment |
| US3950536A (en) | 1974-02-01 | 1976-04-13 | Sol Joseph Barer | N,N-Dichloro substituted aminocarboxylic acids as bactericides and fungicides |
| US4015008A (en) | 1974-02-01 | 1977-03-29 | National Patent Development Corporation | N,N-dichloro substituted aminocarboxylic acids as microbiocides |
| US3966796A (en) | 1974-06-14 | 1976-06-29 | Interx Research Corporation | N-chloro-amino acid derivatives activity |
| US4045578A (en) | 1974-06-14 | 1977-08-30 | Interx Research Corporation | N-chloro-amino acid derivatives exhibiting antibacterial activity |
| US4386103A (en) | 1981-01-30 | 1983-05-31 | Merck & Co., Inc. | Dichloroamino acid derivatives useful as potent germicidal and fungicidal agents |
| US5096700A (en) | 1990-09-28 | 1992-03-17 | The Procter & Gamble Company | Halogenated aminohexanoates and aminobutyrates antimicrobial agents |
| DE4041703C2 (de) | 1990-12-24 | 1993-10-21 | Waldemar Dr Gottardi | Alkalimetallsalze des N-Chlortaurins in kristalliner Form, Verfahren zu deren Herstellung und deren Verwendung |
| JP3759757B2 (ja) * | 1994-01-13 | 2006-03-29 | 相互薬工株式会社 | 殺菌剤 |
| US5753701A (en) | 1996-10-25 | 1998-05-19 | University Of Kentucky | N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters as novel safe agents for water disinfection |
| DE19712565A1 (de) * | 1997-03-25 | 1998-10-01 | Thomas W Dr Stief | Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes |
| DE19816102C1 (de) * | 1998-04-10 | 1999-09-16 | Waldemar Gottardi | Verfahren zum Inaktivieren von Viren in Proteinlösungen, Verwendung von N-Chlortaurin in dem Verfahren sowie nach dem Verfahren hergestellte Proteinlösungen |
| CA2320556A1 (en) | 1999-09-29 | 2001-03-29 | Queen's University At Kingston | N,n-dichlorinated omega amino acids and uses thereof |
| AU2001285944A1 (en) | 2000-09-14 | 2002-03-26 | Waldemar Gottardi | Fungicidal agent containing n-chlorotaurine and use thereof |
| FR2819723B1 (fr) * | 2001-01-23 | 2006-11-17 | Arnaud Mainnemare | Composition halogene, son procede de preparation et ses utilisations |
| WO2004003702A2 (en) * | 2002-06-27 | 2004-01-08 | Geranio Nicholas L | Integrated property database and search engine |
| DK1656095T3 (en) | 2003-08-18 | 2014-03-10 | Novabay Pharmaceuticals Inc | N, N-DIHALOGENG-GENERATED AMINO ACIDS AND DERIVATIVES |
| EP1713785A1 (en) | 2003-12-17 | 2006-10-25 | Rib-X Pharmaceuticals, Inc. | Halogenated biaryl heterocyclic compounds and methods of making and using the same |
| TW200843787A (en) | 2006-12-29 | 2008-11-16 | Novabay Pharmaceuticals Inc | N-halogenated amino compounds and derivatives; compositions and methods of using them |
-
2006
- 2006-01-24 TW TW095102567A patent/TWI386201B/zh not_active IP Right Cessation
- 2006-01-25 CN CNA2006800070563A patent/CN101132785A/zh active Pending
- 2006-01-25 KR KR1020077019438A patent/KR20070098947A/ko not_active Ceased
- 2006-01-25 EP EP06733945.7A patent/EP1896001B1/en not_active Not-in-force
- 2006-01-25 ES ES06733945T patent/ES2421157T3/es active Active
- 2006-01-25 MX MX2007008928A patent/MX2007008928A/es active IP Right Grant
- 2006-01-25 US US11/339,987 patent/US7846971B2/en active Active
- 2006-01-25 AU AU2006208046A patent/AU2006208046B2/en not_active Ceased
- 2006-01-25 JP JP2007553252A patent/JP5329095B2/ja not_active Expired - Fee Related
- 2006-01-25 WO PCT/US2006/002875 patent/WO2006081392A1/en not_active Ceased
- 2006-01-25 CA CA2595889A patent/CA2595889C/en not_active Expired - Fee Related
- 2006-01-25 BR BRPI0607302-6A patent/BRPI0607302A2/pt not_active Application Discontinuation
-
2007
- 2007-07-23 IL IL184771A patent/IL184771A/en active IP Right Grant
- 2007-08-01 ZA ZA2007/06402A patent/ZA200706402B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101132785A (zh) | 2008-02-27 |
| AU2006208046A2 (en) | 2006-08-03 |
| US20060247209A1 (en) | 2006-11-02 |
| WO2006081392A1 (en) | 2006-08-03 |
| TW200640445A (en) | 2006-12-01 |
| IL184771A (en) | 2013-04-30 |
| ES2421157T3 (es) | 2013-08-29 |
| EP1896001A1 (en) | 2008-03-12 |
| ZA200706402B (en) | 2011-12-28 |
| AU2006208046B2 (en) | 2011-03-24 |
| US7846971B2 (en) | 2010-12-07 |
| TWI386201B (zh) | 2013-02-21 |
| AU2006208046A1 (en) | 2006-08-03 |
| KR20070098947A (ko) | 2007-10-05 |
| MX2007008928A (es) | 2007-12-10 |
| CA2595889A1 (en) | 2006-08-03 |
| JP5329095B2 (ja) | 2013-10-30 |
| JP2008531479A (ja) | 2008-08-14 |
| EP1896001B1 (en) | 2013-06-19 |
| BRPI0607302A2 (pt) | 2009-08-25 |
| IL184771A0 (en) | 2007-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2595889C (en) | N-halogenated amino acids and n,n-dihalogenated amino acids in combination with hypohalous acids | |
| US7893109B2 (en) | N,N-dihalogenated amino acids and derivatives | |
| JP5564264B2 (ja) | Ｎ−ハロゲン化アミノ化合物および誘導体 | |
| JP2008531479A5 (cg-RX-API-DMAC7.html) | ||
| HK1117748A (en) | N-halogenated amino acids and n, n-dihalogenated amino acids in combination with hypohalous acids | |
| HK1103713B (en) | N,n-dihalogenated amino acids and derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210125 |